Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:05:44 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:PRPO - PRECIPIO INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PRPO - Q0.25.50·6.200.16.025-0.1801-2.99.352566.214  6.214  5.8014.80  4.751516:00:00Mar 2515 min RT 2¢

Recent Trades - Last 10 of 56
Time ETExPriceChangeVolume
16:00:00Q5.85-0.3251
15:59:34Q5.85-0.32530
15:58:11Q5.90-0.27520
15:57:51Q5.86-0.31516
15:56:26Q5.86-0.3158
15:56:26Q5.90-0.2751
15:56:26Q5.90-0.2753
15:55:55Q6.09-0.0851
15:52:25Q5.90-0.2753
15:48:37Q6.025-0.155

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-25 17:00U:PRPONews ReleasePrecipio Announces Year end 2023 Shareholder Update Call
2024-02-13 10:00U:PRPONews ReleasePrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
2024-02-06 10:00U:PRPONews ReleasePrecipio and Cardinal Health Sign Distribution Agreement for its HemeScreen ‚ ® Portfolio of Molecular assays for Cancer
2024-01-23 10:00U:PRPONews ReleasePrecipio ¢ € ™s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
2024-01-17 10:30U:PRPONews ReleasePrecipio Signs Distribution Agreement For IV-Cell ‚ ® and HemeScreen ‚ ® in Japan
2024-01-02 09:00U:PRPONews ReleasePrecipio Announces Christina Valauri joins the Board of Directors
2023-12-14 16:30U:PRPONews ReleasePrecipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
2023-11-16 17:00U:PRPONews ReleasePrecipio Announces Q3-2023 Shareholder Update Call
2023-10-18 09:00U:PRPONews ReleasePrecipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
2023-10-03 10:00U:PRPONews ReleasePrecipio ¢ € ™s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
2023-09-28 09:00U:PRPONews ReleasePrecipio Continues to Sign New HemeScreen ¢ „ ¢ Customers
2023-09-25 11:00U:PRPONews ReleasePrecipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
2023-09-21 09:00U:PRPONews ReleasePrecipio Takes Final Step Towards Regaining Nasdaq Compliance
2023-09-13 09:30U:PRPONews ReleasePrecipio ¢ € ™s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
2023-08-10 17:00U:PRPONews ReleasePrecipio Announces Q2-2023 Shareholder Update Call
2023-08-08 09:00U:PRPONews ReleasePrecipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
2023-08-03 09:00U:PRPONews ReleasePrecipio ¢ € ™s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
2023-08-01 09:00U:PRPONews ReleasePrecipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
2023-06-14 09:50U:PRPONews ReleasePrecipio ¢ € ™s Omnia ¢ „ ¢ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
2023-06-13 09:00U:PRPONews ReleasePrecipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen ‚ ® Technology